Fenretinide-associated multilayered retinal hemorrhage in a patient with hairy cell leukemia

Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec;41 Suppl:S89-92. doi: 10.3928/15428877-20101031-17.

Abstract

Intravenous fenretinide (4-HPR), a cytotoxic retinoid, is being evaluated as part of a phase I clinical trial for patients with hematologic malignancies. In its orally administered form, it is also being evaluated for the treatment of various malignancies and geographic atrophy in subjects with the dry form of age-related macular degeneration. The authors report a case of acute large subretinal and intraretinal hemorrhage noted immediately after initiation of intravenous fenretinide therapy in a patient with hairy cell leukemia. This case highlights the importance of considering multilayered retinal hemorrhage as a possible side effect of fenretinide therapy, especially in patients with underlying hematologic abnormalities.

Publication types

  • Case Reports
  • Clinical Trial, Phase I

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Female
  • Fenretinide / adverse effects*
  • Humans
  • Infusions, Intravenous
  • Leukemia, Hairy Cell / drug therapy*
  • Middle Aged
  • Retinal Hemorrhage / chemically induced*
  • Retinal Hemorrhage / diagnosis
  • Tomography, Optical Coherence

Substances

  • Antineoplastic Agents
  • Fenretinide